Viking Therapeutics Phase 2b Trial Into Non-Alcoholic Steatohepatitis Meets Primary, Secondary Endpoints

MT Newswires Live11-20 05:51

Viking Therapeutics (VKTX) said late Tuesday that final results from its phase 2b clinical trial showed VK2809 "successfully achieved" its primary and secondary endpoints while demonstrating "excellent tolerability and promising safety."

VK2809 is for patients with biopsy-confirmed non-alcoholic steatohepatitis, also referred to as metabolic dysfunction-associated steatohepatitis, the company said. The results are from 52 weeks of data.

The company reported patients receiving VK2809 demonstrated "statistically significant" reductions in liver fat at Week 12, the primary endpoint.

On the secondary endpoint of non-alcoholic steatohepatitis resolution with no worsening of fibrosis, VK2809-treated patients demonstrated resolution ranging from 63% to 75%, compared with 29% for placebo.

On another secondary endpoint evaluating the proportion of patients experiencing both the resolution of non-alcoholic steatohepatitis and an improvement in fibrosis, VK2809-treated patients demonstrated improvement ranging from 40% to 50%, compared with 20% for placebo, the company added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment